Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Perez

Physical Medicine & Rehabilitation Staten Island, NY Medical Doctor

NPI 1538134226 CMS profile 205734

361 Edison St, Staten Island, NY 10306

Open in the dashboard

General payments

$8,914

543 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Perez of Staten Island, NY is reported in the CMS Open Payments database as having received $8,914 across 543 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,888 98
2024 General $1,232 68
2023 General $1,066 62
2022 General $997 64
2021 General $1,243 78
2020 General $1,065 79
2019 General $1,423 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Perez
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Christopher Perez were reported at $1,888. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Christopher Perez Physical Medicine & Rehabilitation median Middle half National median
2019 $1,423 $133 $45–$390 $163
2020 $1,065 $88 $29–$272 $114
2021 $1,243 $116 $33–$360 $132
2022 $997 $123 $40–$378 $149
2023 $1,066 $131 $43–$396 $160
2024 $1,232 $141 $45–$409 $164
2025 $1,888 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,200 77 payments
  2. Collegium Pharmaceutical, Inc. $1,119 72 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $994 71 payments
  4. Scilex Pharmaceuticals Inc. $939 62 payments
  5. Braeburn Inc. $515 22 payments
  6. Pfizer Inc. $489 28 payments
  7. Forte Bio-Pharma LLC $477 21 payments
  8. Indivior Inc. $456 24 payments
  9. Lundbeck LLC $299 15 payments
  10. Daiichi Sankyo Inc. $265 20 payments
  11. Other $2,160 131 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,893 540 payments
  2. Education $21 1 payment
  3. Gift $0 2 payments
Products named General payments · program years 2019–2025
  1. XTAMPZA $1,119 72 payments
  2. RELISTOR $782 55 payments
  3. ZTLido $712 47 payments
  4. UBRELVY $700 49 payments
  5. BRIXADI $515 22 payments
  6. PROLATE Pain $461 20 payments
  7. PROLATE Pain $461 20 payments
  8. PROLATE Pain $461 20 payments
  9. NALOCET $461 20 payments
  10. QULIPTA $409 19 payments
  11. Other $5,356 320 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

2,541

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$275,421

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

32.6%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 58 $49,465
Diclofenac Sodium Generic 137 $42,154
Ztlido Lidocaine Brand 49 $36,268
Movantik Naloxegol Oxalate Brand 67 $27,023
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 197 $25,352
Ubrelvy Ubrogepant Brand 21 $21,621
Lidocaine Generic 79 $16,986
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 73 $15,479
Oxycodone Hcl Generic 273 $5,639
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 182 $5,618

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$385,697

Of which drugs: $54,411

Medicare patients

605

Average age 72

Services billed

23,390

298 women, 307 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 72%
Diabetes 60%
Ischemic heart disease 45%
Depression 37%
Alzheimer's or dementia 31%
Chronic kidney disease 30%
Heart failure 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 19 9,434 $46,691
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 21 123 $7,092
Injection, methylprednisolone acetate, 1 mg J1010 Office 58 3,787 $377
Injection, methylprednisolone acetate, 20 mg J1020 Office 17 51 $186
Injection, ketorolac tromethamine, per 15 mg J1885 Office 23 95 $49

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
  • Collegium Pharmaceutical, Inc. $209
$209 — —
BRIXADI
  • Braeburn Inc. $179
$179 — —
PROLATE
  • Forte Bio-Pharma LLC $153
$153 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $119
$119 — —
UBRELVY
  • AbbVie, Inc. $102
$102 21 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

543 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record